Connect with us

Hi, what are you looking for?

Stock

AstraZeneca reports COVID vaccine sales of $275 million, expects hit to ease

Stock Markets10 minutes ago (Apr 30, 2021 04:00AM ET)

(C) Reuters. Exterior photos of the North America headquarters of AstraZeneca

By Pushkala Aripaka and Ludwig Burger

(Reuters) – AstraZeneca (NASDAQ:AZN) said its COVID-19 vaccine contributed $275 million to first-quarter sales and shaved three cents per share from its earnings, as it posted better-than-expected results and forecast growth in the second half.

This is the first time the Anglo-Swedish drugmaker has given financial details of the distribution and sales of its vaccine, which it developed with Oxford University. It has said it will not make a profit from the shot during the pandemic.

Vaccine revenue included delivery of about 68 million doses, AstraZeneca said on Friday, adding that sales in Europe, where it faces a legal case, were $224 million, in emerging markets $43 million and $8 million in the rest of the world.

Sales of $275 million for 68 million doses equates to a price tag of around $4 per shot.

The results come after a bruising start to the year as the drugmaker struggles with production of its vaccine and faces a legal battle after cutting deliveries to Europe, while regulators probe rare blood clots in people who got the shot.

AstraZeneca was one of the leaders in the global race to develop a COVID-19 vaccine. Its cheap and easily transportable shot was hailed as a milestone in the fight against the crisis, but has since faced a series of controversies.

In presentation slides published ahead of a media call, AstraZeneca said it was ramping up vaccine supplies with production yields improving, without providing details.

AstraZeneca said it would submit an application for U.S. emergency use in the coming weeks, adding global data from late-stage and emerging real-world data following a roll-out. The vaccine’s efficacy data had also been questioned in the past.

While the coronavirus continues to have a mixed impact on drugmakers, AstraZeneca’s core business has proved resilient.

The company on Friday maintained its guidance for 2021 and predicted better times ahead.

However, the guidance does not include any impact from sales of the vaccine and its $39 billion purchase of Alexion (NASDAQ:ALXN), which is expected to close in the third quarter.

“We expect the impact of COVID to reduce and anticipate a performance acceleration in the second half of 2021,” Chief Executive Pascal Soriot said in statement.

Quarterly sales growth was driven by best-selling lung cancer drug Tagrisso, up 17% to $1.15 billion, while revenues from heart and diabetes drug Farxiga jumped by more than half to a better-than-expected $625 million, on new prescriptions to treat heart failure.

Total revenue of $7.32 billion for the three months to March surpassed analysts’ expectation of $6.94 billion, while core earnings of $1.63 cents per share were also ahead of a consensus of $1.48 per share.

AstraZeneca reports COVID vaccine sales of $275 million, expects hit to ease

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Uncategorized

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.

Uncategorized

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione.

Uncategorized

Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum.

Uncategorized

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora.

Disclaimer: Buzzclever.com it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial or health advice. Copyright © 2021 Buzz Clever. All Rights Reserved